Since the first clinical use of the implantable cardioverter--defibrillator (ICD) in 1980, multiple large randomized controlled trials (RCTs) have been conducted, and ICD guidelines and indications for various patient populations have been emerging as these RCTs conclude. ICDs are indeed beneficial in selected patients; hence, a thorough understanding of indications is critical for daily practice.

In this article, we present a retrospective analysis on how evolving ICD/cardiac resynchronization therapy (CRT) studies have translated into a standard of care at our community-based hospital by guiding us to formulate standard, practical, and update-to-date ICD inclusion and exclusion criteria. Before the establishment of these criteria, there was no systematic method for stratification of patients, and decisions were limited to the discretion of the cardiologist, sometimes with little or no involvement of the cardiac electrophysiologist. This situation necessitated a hospital-wide policy to ascertain appropriate device implantation criteria and guidelines for all patients. After the establishment and execution of the criteria that will be discussed in detail in this paper, the adherence and compliance with current recommendations from CRT trials and standard national guidelines has become close to 100% in our hospital. Cost-effectiveness has greatly improved; institute and device resources are now better utilized.

Clinical trial review {#S0002}
=====================

Since 1980, multiple large RCTs have been conducted. AVID (Antiarrhythmic Versus Implantable Defibrillator) ([@CIT0001]) concluded that the ICD is superior to medication for secondary prevention of ventricular tachycardia (VT)/ventricular fibrillation (VF). The survival benefit with ICD implantation in comparison with standard medical therapy for secondary prevention of VT/VF has been replicated by two smaller trials \[CIDS ([@CIT0002]) and CASH ([@CIT0003])\]. These findings have established the secondary prevention of sudden cardiac death (SCD) as a Class I indication for ICD placement.

As for primary prevention of SCD, the MADIT ([@CIT0004]), MADIT-II ([@CIT0005]), and MUSTT ([@CIT0006]) trials showed that ICDs significantly improved survival in high-risk patients with coronary artery disease (CAD) and ischemic cardiomyopathy. High risk is defined as: CAD, prior myocardial infarction, left ventricular ejection fraction (LVEF) no greater than 35%, non-sustained VT on ambulatory monitoring, VT inducible by programmed stimulation, and failure of intravenous procainamide to prevent inducibility. In contrast, CABG Patch ([@CIT0007]) showed ICDs do not improve survival in high-risk patients after CABG up to 32 months; DINAMIT ([@CIT0008]) showed ICD therapy does not reduce overall mortality in high-risk patients who have recently had acute myocardial infarction (AMI) up to 40 days.

The DEFINITE trial ([@CIT0009]) showed a strong trend toward ICD benefit over the standard-therapy group for non-ischemic cardiomyopathy. SCD-HeFT ([@CIT0010]) was the largest primary prevention ICD clinical trial, which recruited patients with either non-ischemic or ischemic cardiomyopathy, LVEF \<35%, and New York Heart Association (NYHA) functional Class II or III congestive heart failure (CHF). It concluded that ICD reduced overall mortality by 23% in CHF patients. SCD-HeFT also defined patient selection for ICD therapy to patients with LVEF \<35% and NYHA Class II or III CHF.

Despite the lack of large-scale RCTs, ICDs are usually a Class IIa recommendation for patients with uncommon conditions such as infiltrative and inherited diseases that are associated with a high risk of SCD. Infiltrative diseases include cardiac sarcoidosis, and less commonly, amyloidosis. An ICD is indicated when the conditions are accompanied by sustained or non-sustained VT, regardless of LVEF. Inherited cardiac diseases include hypertrophic cardiomyopathy (HOCM), arrhythmogenic right ventricular dysplasia, Brugada syndrome, long QT syndrome, and catecholaminergic polymorphic VT.

MIRACLE ([@CIT0011]), COMPANION ([@CIT0012]), and MADIT-CRT ([@CIT0013]) established the base for CRT. The COMPANION study enrolled patients with low LVEFs, QRS duration \>120 ms, and NYHA Class III or IV (the only study to evaluate ICDs in NYHA Class IV), and showed that CRT improved LVEF, heart failure symptoms, and reduced the mortality rate in patients with NYHA Class III--IV heart failure and wide QRS interval regardless of ischemic or non-ischemic etiology. MADIT-CRT showed ICDs decrease non-fatal heart failure events in mild CHF (NYHA Classes I and II), LVEF \<30%, and QRS duration \>130 ms. It further proved that patients with a QRS duration \>150 ms benefit from CRT the most.

Methods {#S0003}
=======

Translating the results of these emerging studies became critical to our clinical practice for patient care at a community-based hospital. We established ICD/CRT inclusion/exclusion criteria in our hospital by integrating the results of these major trials.

Over 450 patients who were admitted to our hospital during the past year for either ICD implantation or for ICD-related events were extensively reviewed; among these, 13 cases were selected to represent major indications and contraindications of ICDs in our practice. These cases presented here cover ICD indications for the secondary prevention of SCD, primary prevention of SCD in patients with CHF that resulted from either CAD or non-ischemic cardiomyopathy, and indications for infiltrative cardiomyopathy and inherited conditions. A greater than 1 year of life expectancy with reasonable functionality is a prerequisite to qualify for a device. We also discussed the potential benefits of ICDs with and without CRT in certain populations of patients that have not been adequately evaluated by currently available RCTs, including alcoholic, elderly, female, or end-stage renal disease (ESRD)/hemodialysis (HD) patients. Finally, we addressed the risks, complications, and contraindications of ICDs, as well as the application of an external wearable defibrillator, which has comparable survival benefit with ICDs ([@CIT0014]), in AMI or status post (s/p)-CABG during the mandatory waiting period for an ICD.

Results {#S0004}
=======

[Table 1](#T0001){ref-type="table"} shows the inclusion/exclusion criteria of ICD/CRTs in our hospital. These criteria are based on updated CRT results and recommendations. Execution of these criteria improves the adherence and compliance of ICD guidelines for daily patient care in our hospital.

###### 

Easton Hospital ICD criteria

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Secondary prevention
   1. Documented episodes of cardiac arrest due to VT/VF, not due to a transient or reversible cause
   2. Documented sustained VT, either spontaneous or induced by EP, not associated with AMI and not due to a transient or reversible cause.
  Primary prevention
   1. Documented familiar or inherited conditions with high risk of life-threatening VT, such as long QT syndrome, hypertrophic obstructive cardiomyopathy, etc.
   2. CAD with all of the following:
    Prior MI \>40 days (MADIT I & MUSTT)
    LVEF \<35%
    VT/VF inducible and sustained at EP study
    EP study greater than 4 weeks post-qualifying MI
   3. Prior MI with all of the following (MADIT II):
    LVEF \<30%
    NYHA Class II or III
    No cardiogenic shock or hypertension in stable rhythm
   4. Ischemic dilated cardiomyopathy with both of the following (SCD-HeFT):
    NYHA Class II or III
    LVEF \<35%
   5. Non-ischemic dilated cardiomyopathy with all of the following (SCD-HeFT):
    Documented duration \>3 months
    NYHA Class II or III
    LVEF \<35%
   6. Severe CHF with all of the following:
    Meets coverage requirements for CRT
    NYHA Class IV
    QRS \>120 ms
  Exclusion criteria
   1. MI \<40 days
   2. CABG or PCI \<90 days
   3. NYHA Class IV who do not meet requirements for CRT Rx
   4. Candidate for coronary revascularization
   5. VT/VF or CHF due to reversible cause
   6. No reasonable expectation of survival with a good functional status for more than 1 year.
  Class I recommendation for CRT
   LVEF \<30%
   Dilated LV cavity with severe systolic dysfunction
   Recurrent CHF (NYHA Class III or ambulatory Class IV) despite optimal medical therapy, \>3--9 months in duration
   QRS duration \>120 ms (best responders: LBBB and QRS-d \>150 ms)
   Ventricular tachyarrhythmia (VT/VF)
   Sinus rhythm best response (AV synchrony and VV synchrony)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

CHF, congestive heart failure; CRT, cardiac resynchronization therapy; ICD, implan cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; Rx, treatment; VF, ventricular fibrillation; VT, ventricular tachycardia.

In [Table 2](#T0002){ref-type="table"}, we list 13 cases representing the most common clinical situations encountered in our clinical practice during last year. For each case, a brief clinical history, the electrophysiology study results leading to a guideline-supported device indication (as referenced in [Table 1](#T0001){ref-type="table"}), and the final treatment delivered are outlined. A 12-lead EKG for each case is also shown following the table. Major categories of patients include: 1) patients who meet primary or secondary ICD criteria; 2) patients who meet exclusion criteria; 3) patients who need mandatory waiting time; and 4) patients who meet criteria for CRT.

###### 

Cases discussion of the criteria described in [Table 1](#T0001){ref-type="table"}

  --
  --

Special considerations {#S0005}
======================

The potential benefits of ICDs with/without CRT in certain patient populations have not been adequately evaluated by currently available RCTs.

Alcoholic cardiomyopathy and ICD {#S0005-S20001}
--------------------------------

The ICD is indicated for cardiac arrhythmia and/or CHF associated with alcoholic cardiomyopathy. Alcohol can trigger atrial fibrillation, which can make an ICD fire inappropriately. Although new versions of ICD can distinguish atrial fibrillation from other lethal arrhythmias and therefore have less inappropriate firings, abstaining from alcohol is a must for patients with alcoholic cardiomyopathy.

Age, gender, and ICDs {#S0005-S20002}
---------------------

Both the elderly (\>80 years old) and female patients are underrepresented in current ICD trials, even though about 20% of ICDs are implanted in these two patient populations. Meta-analysis data from available trials suggest that ICDs do not reduce overall mortality in the elderly, which is likely due to a higher incidence of non-arrhythmic death as compared with younger patients ([@CIT0015]). However, due to small population sizes in these studies as well as wide confidence intervals (95% CI, 0.29--1.08), we do not consider age to be exclusion criterion in our practice. Similarly, meta-analysis data also found that ICDs do not confer significant overall mortality benefit in women ([@CIT0016]). This is believed to be because SCD has a weaker impact on total mortality in women than in men -- hence, the higher ICD benefit in men. Further larger-scale studies focusing on these patient populations are warranted, and careful risk stratification in clinical practice is important to avoid overgeneralization of current ICD recommendations.

ESRD and ICD {#S0005-S20003}
------------

While up to 10% of ESRD patients have an ICD implanted, the survival benefit in this population is unclear ([@CIT0017]), most likely due to the presence of multiple severe comorbidities. Transvenous ICD leads are associated with central vein stenosis resulting in significant adverse consequences for arteriovenous access (in up to 20% of ESRD patients). Infections associated with ICD leads are more frequent and associated with worse outcomes in ESRD patients ([@CIT0018]). An external wearable defibrillator is an alternative for ESRD patients who do not yet meet criteria for permanent ICD therapy or are experiencing serious side effects.

Complications {#S0005-S20004}
-------------

Other than venous stenosis and systemic or local infections, patients can experience discomfort associated with ICD implantation and shocks. ICD shocks can also lead to anxiety as well as panic disorders and even agoraphobia. One of our recent studies showed that underlying malignancy is also a significant risk factor for ICD pocket infection ([@CIT0019]).

Conclusions {#S0006}
===========

The ICD has a wide spectrum of clinical applications. A thorough understanding of its indications is critically important in daily practice. At our hospital, ICD inclusion and exclusion criteria have been established based on data from major RCT results. These criteria are practical and up to date. They help to standardize patient care in terms of ICD/CRT implantation. It is evident from our cases that we stress on contraindications, mandatory waiting periods and maximal/optimal medical therapy prior to device implantation. Case 8 and 12, in particular, highlight reversible causes of VT/VF as exclusion criteria. We believe this represents a practical translation of emerging CRTs that results in better patient care in our practice at a community-based hospital. Further study is certainly necessary to assess the impact of the ICD Criteria in our institution by comparing implant appropriateness both before and after the institution of the criteria with significant randomized samples sizes.

ICDs are indeed beneficial in selected patients. Mortality benefits have not been proven in female patients, the elderly, ESRD, and non-ischemic cardiomyopathy patients. In addition, ICD shocks can be painful, reduce quality of life, and increase anxiety in patients. Patients should be well informed of all benefits and risks of the ICD before implantation.

We thank Drs. Krishnamurthy, Snyder and Livert for critical review and helpful comments.

Conflict of interest and funding {#S0007}
================================

The authors declare no conflicts of interest and funding.
